Trial reportArthritis research & therapy2026
Upadacitinib for refractory Behcet's syndrome: a multi-centre, single-arm trial.
Trial report in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of upadacitinib in patients with refractory Behcet’s syndrome (BS).
methodsA multicentre, single-arm trial was conducted from February 2023 to August 2025. Eligible patients had BS refractory to at least two immunosuppressive agents or one targeted therapy for a minimum of 6 months. Participants discontinued previous targeted therapies and received upadacitinib 15 mg/day for up to 48 weeks, in addition to their ongoing glucocorticoid and immunosuppressant regimens. Clinical features, inflammatory markers, imaging findings, and treatment data were collected throughout follow-up. The primary endpoint was the overall response rate (ORR; complete response [CR] plus partial response [PR]) at 24 weeks.
resultsTwenty-seven patients (16 male; median age 36 years) were enrolled, with a median baseline BDCAF score of 4 (range: 2–7). Affected systems included the mucocutaneous, articular, gastrointestinal, cardiovascular, and ocular systems. The ORR at 24 weeks was 85.2% (23/27), comprising 16 CRs and 7 PRs. Significant reductions were observed in median BDCAF scores, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and glucocorticoid dosage by week 24. Among the 23 patients who achieved remission at week 24, median CRP and ESR levels at 48 weeks were significantly lower than those at 24 weeks. For clinical responses across different systems, CR was achieved in 3 (100.0%) with cardiovascular involvement, 5 (83.3%) with ocular symptoms, 10 (76.9%) with gastrointestinal involvement, 16 (59.3%) patients with mucocutaneous symptoms, and 1 (16.7%) with articular involvement at 24 weeks. Three patients experienced relapse during the follow-up. No serious adverse events were reported.
conclusionUpadacitinib represents a potential therapeutic option for patients with refractory BS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.